Figure 2.
Mechanism and prevention of antigen loss variants post CD19 CAR T-cell therapy. (A) Mechanism of CD19-targeted immune escape. (B) CAR T-cell products to enable dual targeting of CD19 and CD22.
Mechanism and prevention of antigen loss variants post CD19 CAR T-cell therapy. (A) Mechanism of CD19-targeted immune escape. (B) CAR T-cell products to enable dual targeting of CD19 and CD22.